Browsing: Therapeutics

A small randomized three-arm trial comparing empagliflozin, sitagliptin, and metformin on glycemic and cardio-metabolic parameters in type 2 diabetes, with significance shown mainly against the metformin arm. PICO summary and expert commentary.

In the SOGALDI-PEF crossover trial, adding spironolactone to dapagliflozin produced a modest 11% NT-proBNP reduction in HFmrEF/HFpEF, offset by eGFR decline and higher potassium. PICO summary and expert commentary.

An RCT finds adding semaglutide to metformin improves weight, testosterone, and natural pregnancy rates in women with PCOS. PICO summary and expert commentary.

A small 52-week single-centre randomised trial found once-weekly semaglutide shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.

Clinical Context SGLT2 inhibitors like canagliflozin are cornerstone medications for type 2 diabetes, providing glycemic control alongside cardiovascular and renal…

A double-blind randomised trial of dapagliflozin versus placebo for myocardial fibrosis on cardiac MRI in 100 patients with type 2 diabetes and HFpEF. PICO summary and expert commentary.

An RCT finds the GLP-1 analogue Ebenatide improves glycaemia, time in range, and body composition in type 2 diabetes, confirming a class effect. PICO summary and commentary.

An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.

Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…

Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…